Welcome to our dedicated page for Allogene Therapeutics news (Ticker: ALLO), a resource for investors and traders seeking the latest updates and insights on Allogene Therapeutics stock.
Allogene Therapeutics, Inc. (Nasdaq: ALLO) is a clinical-stage biotechnology company focused on the development and commercialization of allogeneic chimeric antigen receptor T-cell (AlloCAR T™) therapies for cancer and autoimmune diseases. Leveraging the expertise of former Kite Pharma executives, Allogene aims to revolutionize cancer treatment with innovative off-the-shelf CAR T solutions. These therapies, derived from healthy donor cells, provide a scalable and readily available option, eliminating the lengthy and complex process of personalized cell therapy.
The company's portfolio includes 16 pre-clinical T cell therapy assets and UCART19, an allogeneic CAR T therapy in phase 1 development for acute lymphoblastic leukemia (ALL). Notable core programs target various malignancies such as lymphoma, leukemia, solid tumors, and autoimmune diseases. Among its leading investigational products is cemacabtagene ansegedleucel (cema-cel), currently undergoing pivotal phase 2 ALPHA3 trials for large B-cell lymphoma (LBCL) and phase 1 trials for relapsed/refractory chronic lymphocytic leukemia (CLL). ALLO-316, aimed at renal cell carcinoma (RCC), and ALLO-329, targeting autoimmune diseases with Dagger® technology, further strengthen Allogene's robust pipeline.
Allogene collaborates with leading biotech firms like Foresight Diagnostics and Arbor Biotechnologies to enhance its clinical development capabilities. Recent achievements include strategic partnerships and a $15 million grant from the California Institute for Regenerative Medicine (CIRM) supporting the development of ALLO-316. Financially, Allogene reported a strong cash runway extending into 2026, with latest funding rounds ensuring continued support for its R&D initiatives.
Stay informed on Allogene's progress as it drives the future of allogeneic CAR T therapy, providing broader patient access and more efficient cancer treatment options.
Allogene Therapeutics, Inc. (Nasdaq: ALLO) announced it will present updated data from the Phase 1 ALPHA/ALPHA2 trials of ALLO-501 and ALLO-501A at the ASCO Annual Meeting from June 2-6, 2023. These trials assess the safety and preliminary efficacy of the allogeneic CAR T cell products targeting CD19. Allogene is also enrolling patients in the Phase 2 ALPHA2 trial for large B cell lymphoma (LBCL). The data presentation will feature results that highlight the potential of ALLO-501 and ALLO-501A to induce durable responses in relapsed/refractory LBCL. The FDA has granted ALLO-501A RMAT designation, indicating its potential for expedited development. Allogene aims to set a new standard in CAR T therapies.
FAQ
What is the current stock price of Allogene Therapeutics (ALLO)?
What is the market cap of Allogene Therapeutics (ALLO)?
What is Allogene Therapeutics, Inc.?
What are Allogene's core products?
What is unique about Allogene's therapies?
Who are Allogene's key partners?
In which clinical trials is cema-cel involved?
What recent financial achievement did Allogene secure?
How does Allogene's financial outlook appear?
What is the focus of Allogene's ALLO-316 trial?
What is the Dagger® technology used in ALLO-329?
What is the goal of Allogene's therapies?
